Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

 
• By Joseph Haas

The blockbuster GLP-1 analog demonstrated a capability for fibrosis reduction and disease resolution in the Phase III ESSENCE study. The firm plans to file for approval in 2025.

Novo Nordisk's semaglutide hits both primary endpoints in a Phase III NASH study (Shutterstock)

More from Clinical Trials

More from Therapy Areas